Notice of Correction (DOI:10.1016/j.jtcvs.2008.11.016);Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 3, 2009, Pages 605-609

  Cerfolio, Robert J ^a   Bryant, Ayesha S ^a   Talati, Amar A ^b   Cerfolio, Robert M ^b   Winokur, Thomas S ^b  

^a Kentucky   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 60949088038     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.04.018     Document Type: Erratum

References (24)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Headrick R., Nichols III F.C., Miller D.L., et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 73 (2002) 1697-1702
3. Ellis Jr. F.H., Heatley G.H., Krasna M.J., et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 113 (1997) 836-846
4. Killinger Jr. A., Rice T.W., Adelstein D.J., et al. Stage II esophageal carcinoma: the significance of T and N. J Thorac Cardiovasc Surg 111 (1996) 935-940
5. Bryant A.S., and Cerfolio R.J. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?. Ann Thorac Surg 84 (2007) 1092-1097
6. Nabi H.A., and Zubeldia J.M. Clinical applications of F18-FDG in oncology. J Nucl Med Technol 30 (2002) 3-9
7. Cerfolio R.J., Bryant A.S., Ohja B., Bartolucci A.A., and Eloubeidi M.A. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 (2005) 1232-1241
8. Pearson F.G., and Mathisen D.J. Esophageal Surgery + Thoracic Surgery. 1st ed (2002), Churchill Livingstone, London, UK 669-676
9. Cerfolio RJ, Bryant AS. Is botulism toxin injection the optimal treatment of the pylorus during Ivor Lewis esophagogastrectomy. J Cardiovasc Surg. (in press).
10. Cerfolio R.J., Bryant A.S., and Maniscalco L.M. A nondivided intercostal muscle flap further reduces pain of thoracotomy: a prospective randomized trial. Ann Thorac Surg 85 (2008) 1901-1907
11. Cerfolio R.J., Bryant A.S., Patel B., and Bartolucci A.A. Intercostal muscle flap reduces the pain of thoracotomy: a prospective randomized trial. J Thorac Cardiovasc Surg 130 (2005) 987-993
12. Cerfolio R.J., Prince T.N., Bryant A.S., Sale Bass C., and Bartolucci A.A. Intracostal sutures decrease the pain of thoracotomy. Ann Thorac Surg 76 (2003) 407-411
13. DeLong E.R., DeLong D.M., and Clark-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves; a nonparametric approach. Biometrics 44 (1988) 837-845
14. Akhurst T., Downey R.J., Ginsberg M.S., et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 23 (2002) 259-264
15. Cerfolio R.J. Positron emission tomography scanning with 2-fluoro-2-deoxyglucose as a predictor of response for non-small cell cancer. J Thorac Cardiovasc Surg 12 (2003) 938-944
16. Cerfolio R.J., Bryant A.S., Winokur T.S., Ohja B., and Bartolucci A.A. Repeat FDG-PET after neoadjuvant therapy is a predictor of a pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78 (2004) 1903-1909
17. Port J.L., Kent M.S., Korst R.J., et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 77 (2004) 254-259
18. Cerfolio R.J., Bryant A.S., Ohja B., et al. The accuracy of endoscopic ultrasonography with fine needle aspiration, integrated positron emission tomography with computed tomography and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 (2005) 1232-1241
19. Port J.L., Lee P.C., Korst R.J., et al. Positron emission tomography scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 84 (2007) 393-400
20. Cerfolio R.J., Bryant A.S., Ohja B., et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130 (2005) 151-159
21. Cerfolio R.J., and Bryant A.S. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology and survival. Ann Thorac Surg 82 (2006) 391-395
22. Mamede M., Abreu E.L.P., Oliva M.R., et al. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 30 (2007) 377-388
23. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78 (2004) 1152-1160
24. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 (2007) 1385-1391